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ABSTRACT
HIV-1 uses a programmed -1 ribosomal frameshift
to synthesize the precursor of its enzymes, Gag-Pol.
The frameshift efficiency that is critical for the virus
replication, is controlled by an interaction between
the ribosome and a specific structure on the viral
mRNA, the frameshift stimulatory signal. The rate of
cap-dependent translation initiation is known to be
altered by the TAR RNA structure, present at the
5’ and 3’ end of all HIV-1 mRNAs. Depending upon
its concentration, TAR activates or inhibits the
double-stranded RNA-dependent protein kinase
(PKR). We investigated here whether changes in
translation initiation caused by TAR affect HIV-1
frameshift efficiency. CD4+ T cells and 293T cells
were transfected with a dual-luciferase construct
where the firefly luciferase expression depends
upon the HIV-1 frameshift. Translation initiation
was altered by adding TAR in cis or trans of the
reporter mRNA. We show that HIV-1 frameshift
efficiency correlates negatively with changes in the
rate of translation initiation caused by TAR and
mediated by PKR. A model is presented where
changes in the rate of initiation affect the probability
of frameshifting by altering the distance between
elongating ribosomes on the mRNA, which influ-
ences the frequency of encounter between these
ribosomes and the frameshift stimulatory signal.
INTRODUCTION
The precursor of HIV-1 structural proteins, Gag, and the
precursor of the viral enzymes, Pol, are translated from
the full-length viral messenger RNA (mRNA). Gag is
produced by conventional translation whereas Pol
requires a programmed -1 ribosomal frameshift during
the elongation step of translation, which generates the
fusion protein Gag-Pol (1, reviewed in 2,3). Previous
studies showed that a 2- to 20-fold increase in the Gag-Pol
to Gag ratio prevents viral infectivity (4–7) and our group
showed that a decrease in the frameshift eﬃciency as low
as 30% severely impairs the replication of the virus in
cultured cells (8). The Gag-Pol to Gag ratio is therefore
critical for viral infectivity and the programmed –1
frameshift that determines this ratio represents an inter-
esting target for the development of novel antiretroviral
agents against HIV-1.
The HIV-1 frameshift event requires two cis-acting
elements in the viral mRNA: a slippery sequence,
UUUUUUA, where the frameshift occurs (1, reviewed
in 2,3), followed by an irregular stem-loop (9–11), the
frameshift stimulatory signal, that makes the ribosomes
pause over the slippery sequence and controls the frame-
shift eﬃciency. Only a fraction of the ribosomes that
encounter the stimulatory signal make a frameshift. After
the pause, the ribosomes unfold the signal, which can
reform after their passage.
HIV-1 can use a cap-dependent mechanism to initiate
translation of its mRNAs, like most eukaryotic mRNAs
(for a review on translation initiation, see 12–15). There
are two major control steps in eukaryotic cap-dependent
translation initiation (see details in Figure 1A). One is the
binding of the initiator tRNA, Met-tRNAi
Met, to the 40S
ribosomal subunit, which requires the participation of the
initiation factor 2 (eIF2) associated to GTP. The other one
is the binding of the 40S subunit bearing the ternary
complex to the 50 cap structure of the mRNA, which is
controlled by the eIF4F complex. Double-stranded RNA
(dsRNA), such as the TAR RNA structure, can modify
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response element, is a 59-nt stem-bulge-loop structure
present at the 50 and 30 end of all HIV-1 mRNAs in the
nucleus and the cytoplasm (reviewed in 16). It is also
present under a free form of 58-66nt in the cytoplasm of
cells infected with the virus (17,18). In the nucleus, TAR
mediates transcription activation by binding to the viral
Tat protein and the cellular cyclinT protein (19,20). In the
cytoplasm, a low concentration of TAR activates PKR,
the dsRNA-dependent protein kinase, whereas a higher
concentration of TAR inhibits this kinase by blocking its
dimerization, which is essential for its activity (reviewed
in 21). When PKR is activated, it phosphorylates the a
subunit of eIF2, interfering with translation initiation,
whereas, when it is inhibited, the amount of eIF2
phosphorylated decreases and the rate of translation
initiation increases.
In this study, we investigated whether the presence of
TAR aﬀects HIV-1 frameshift eﬃciency in relationship
with the changes it causes in the rate of cap-dependent
translation initiation. To this end, we used a dual-
luciferase construct (8) which expresses the Renilla
luciferase (Rluc) and the ﬁreﬂy luciferase (Fluc) separated
by HIV-1 frameshift region as a fusion protein. Rluc is
expressed following conventional rules of translation
whereas Fluc expression requires a -1 frameshift in the
HIV-1 frameshift region. This type of construct is adapted
from Grentzmann et al. (22), who pioneered the use of a
dual-luciferase reporter for studying recoding signals.
CD4+ T cells (Jurkat) or 293T cells were transfected
with the dual-luciferase plasmid and TAR was added
either in cis or in trans of the reporter mRNA. Several
conditions were assayed to characterize the eﬀect of TAR
on frameshift eﬃciency and the involvement of PKR in
this eﬀect, such as the introduction of a small or a large
amount of TAR in the cells, the use of mutants of TAR
that cannot perturb PKR activity and the silencing of
PKR expression with short interfering RNA (siRNA).
Our results show that HIV-1 frameshift eﬃciency
increases at a low concentration of TAR, when cap-
dependent translation initiation is slowed down, whereas
it decreases at a high concentration of TAR, when
translation initiation is stimulated. These eﬀects were
shown to be dependent on PKR. A model is presented
which relates the eﬀects of TAR on frameshift eﬃciency to
changes in the spacing between the elongating ribosomes
on the mRNA caused by changes in the rate of translation
initiation. Such changes aﬀect the frequency of encounter
between the ribosomes and the frameshift stimulatory
signal.
MATERIALS AND METHODS
Plasmids
To measure HIV-1 frameshift eﬃciency, we used the dual-
luciferase reporters pDual-HIV(-1) and (0) (8). These
plasmids are derived from pcDNA3.1Hygro+
(Invitrogen) and contain the HIV-1 frameshift region
inserted between the coding sequences of the Renilla
Figure 1. HIV-1 frameshift eﬃciency increases in the presence of inhibitors of cap-dependent translation initiation. (A) Major control steps of
cap-dependent translation initiation in eukaryotes (15). The ﬁgure is adapted from Gebauer and Hentze (14). Only the factors we refer to in the text
are named. The 40S ribosomal subunit associates with the ternary complex [initiation factor 2 (eIF2) plus GTP plus the initiator tRNA,
Met-tRNAi
Met] and with other factors, and binds to the 50 cap structure of the mRNA. This binding requires the eIF4F complex formed by three
initiation factors: eIF4E, the cap-binding protein, eIF4G, a scaﬀold protein and eIF4A, a RNA helicase that unfolds secondary structures. After each
round of initiation, eIF2 is released from the ribosome in association with GDP. Phosphorylation of the a subunit of eIF2 (eIF2-a) prevents the
recycling of eIF2-GDP in eIF2-GTP, blocking translation initiation. Thapsigargin induces endoplasmic reticulum stress, which stimulates the PERK
kinase that phosphorylates eIF2-a, reducing the level of functional eIF2 (55–57). Rapamycin shuts down the mammalian target of rapamycin
(mTOR) pathway, which blocks the phosphorylation of the translation repressor 4E-BP, and hypophosphorylated 4E-BP sequesters the initiation
factor eIF4E (58,59). Hippuristanol is a selective inhibitor of eIF4A (60), which interferes with the binding of the 40S subunit to the mRNA.
(B) Plasmid pDual-HIV contains the Rluc and the Fluc coding sequences under the control of a CMV promoter and separated by the HIV-1 frameshift
region. (C) The frameshift eﬃciency was assessed in lysates from Jurkat cells transfected with 2mg of pDual-HIV(-1) or (0) and, subsequently, treated
with thapsigargin, rapamycin or hippuristanol or left untreated (see ‘Materials and Methods’ section for details). The frameshift eﬃciency with untreated
cells transfected with pDual-HIV was arbitrarily set at 100%. Results are the means SD of at least four independent experiments.
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Expression of these genes is under control of a CMV
promoter, which is followed by a T7 promoter. Plasmid
pDual-HIV(0) diﬀers from pDual-HIV(-1) by the addition
of an adenine after the slippery sequence in the frameshift
region. Derivatives of pDual-HIV(-1) and (0) were
constructed where the TAR sequence was inserted after
the CMV and T7 promoters. A TAR-containing fragment
ﬂanked with HindIII sites obtained from pcDNA3-
RSV-TAR-Rluc plasmid (23), a kind gift from
L. DesGroseillers (Universite ´ de Montre ´ al), was cloned
in the HindIII site of pDual-HIV to produce pDual-
HIV-TAR(-1) and (0), where the TAR sequence is located
at a distance of about 40nt from the 50 end of the reporter
mRNA. To produce pDual-HIV-50TAR(-1) and (0),
where the TAR sequence is at a larger distance from the
50 end of the reporter mRNA, a cassette of a 50-nt non-
coding sequence was inserted in the AﬂII site of pDual-
HIV, followed by the insertion of TAR immediately after
these 50nt, in the HindIII site. The oligonucleotides for
the cassette were cass50nt-fwd and cass50nt-rev (see the
sequence of all the oligonucleotides used in this study in
Table 1 of the Supplementary Data). Plasmid pTAR,
which expresses the free TAR sequence in trans from the
reporter mRNA, was made by inserting the TAR-
containing fragment ﬂanked with HindIII sites into the
HindIII restriction site of pcDNA3.1Hygro+. Derivatives
of pTAR, pTARuucg
  and pTARibulge
 , which
express mutants of TAR, were constructed by cloning
oligonucleotide cassettes (cass_TAR-uucg
  fwd and
cass_TAR-uucg
  rev or cass_TAR-bulge
  fwd and
cass_TAR-bulge
  rev) between the two NheI restriction
sites present in the TAR sequence of pTAR. In the ﬁrst
mutant, the upper loop, CUGGGA, is replaced with
UUCG and, in the second mutant, the bulge UCU
preceding the upper loop is deleted. Plasmid pCGNiC
[a generous gift from N. Hernandez, Cold Spring Harbor
Laboratory (24)] expresses a mutant of the TAR-binding
protein Tat (Tat
 ), named TatC30,31A.
Transfectionof Jurkatand HEK 293T cells
Jurkat cells (CD4+ T cells) were maintained in RPMI
1640 medium (Wisent) supplemented with 10% (v/v) FBS
(Wisent) and HEK 293T cells (human embryonic kidney
cells transformed with adenovirus and simian virus 40
large-T) were maintained in DMEM (Gibco) supplemen-
ted with 10% (v/v) FBS. Transfections were performed
with polyethylenimine (PEI) (Polysciences, Inc.) in six-well
plates containing Jurkat cells (1.2 10
6), 293T cells
(4.0 10
5) or 293T stable transfectants (6.0 10
5 cells)
expressing a dual-luciferase HIV reporter (see subse-
quently). PEI was added drop-wise to serum-free
medium and incubated 10min at room temperature.
In parallel, serum-free medium was added to DNA.
The diluted PEI was added to the DNA solution (PEI to
DNA ratio of 2:1) and incubated at least 15min at room
temperature. An empty plasmid, pcDNA3.1Hygro+,
was added, when required, to maintain an equivalent
DNA input.
Effect of translation inhibitors
Translation inhibitors were added as follows: rapamycin
(Fisher), 16h post-transfection (ﬁnal concentration:
25nM), hippuristanol (a generous gift from J. Pelletier,
McGill University), 24h before harvest (ﬁnal concentra-
tion: 400nM) and thapsigargin (Sigma), 4h before harvest
(ﬁnal concentration: 300nM). Transfected cells were
harvested 48h post-transfection. Non-adherent cells were
centrifuged at 3000g for 5min, washed with PBS and
lysed in 100ml of Cell Passive Lysis Buﬀer (Promega).
Adherent cells were washed with PBS and lysed in 400ml
of Cell Passive Lysis Buﬀer. Cell lysates were centrifuged
2min at 13000g at 48C to remove cell debris, before
luciferase assays.
Selection ofstable 293T transfectants expressing a
dual-luciferase HIVreporter
Plasmids pcDNA5-Dual-HIV(-1) and (0) were made by
inserting the HindIII–ApaI fragment from pDual-HIV(-1)
or (0), respectively, into pcDNA5-FRT (Invitrogen),
which contains a resistance gene to hygromycin B.
An in-frame construct without the HIV-1 frameshift
region was generated by cloning an oligonucleotide
cassette (inframe-fwd and inframe-rev) into the KpnI
and BamHI restriction sites of linearized pDual-HIV.
In pDual-in-frame, the luciferase coding sequences are in
the same reading frame and separated by a short linker.
The HindIII–ApaI fragment from pDual-in-frame was
cloned into pcDNA5-FRT.
Cell lines stably expressing the (-1) or (0) dual-luciferase
HIV reporter, or the in-frame construct, were generated
following the manufacturer’s instructions, using 293T
Flp-in
TM cells (Invitrogen). Individual clones that stably
incorporated the plasmids were selected on the basis of
their resistance to hygromycin B (Wisent) (250mg/ml) and
maintained in hygromycin B.
Silencing ofPKR withsiRNA
293T transfectants (6.0 10
5cells) stably expressing the
(-1) and (0) dual-luciferase HIV reporter were transfected
with 150ng of the PKR ShortCutsiRNA Mix or the
eGFP ShortCutsiRNA Mix (New England BioLabs),
using PEI. The TAR-expressing plasmids were transfected
24h after the transfection with a siRNA mix. Cells were
harvested 48h after this second transfection and luciferase
assays were performed.
Control of PKR silencing bywestern blotting
293T transfectants, transfected with a siRNA mix,
as described above, were harvested 48h after the
transfection, washed in PBS and lysed in 100ml of Ripa-
Doc (ﬁnal concentration: 140mM NaCl, 8mM Na2HPO4,
2mM NaH2PO4, 1% Nonidet P-40, 0.5% sodium
deoxycholate and 0.05% sodium dodecyl sulphate),
containing a cocktail of protease and phosphatase
inhibitors. Equal amounts of proteins (15mg) were
separated on a 10% SDS–PAGE gel, transferred on
a nitrocellulose membrane and immunoblotted with a
mouse anti-PKR hybridoma supernatant (clone F9)
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and a horseradish peroxidase-conjugated goat anti-mouse
secondary antibody (Amersham) diluted 1/1500. After
detection of the antigen–antibody complexes, the mem-
brane was washed with 25ml of stripping buﬀer (ﬁnal
concentration: 0.08M b-mercaptoethanol, 2% sodium
dodecyl sulphate and 0.06M Tris–HCl, pH 6.9) for
30min at 508C, and immunoblotted with a mouse anti-
a-tubulin monoclonal antibody (clone B-5-1-2 Sigma)
diluted 1/5000 and a horseradish peroxidase-conjugated
goat anti-mouse secondary antibody diluted 1/1500.
Antigen–antibody complexes were detected with an
enhanced chemiluminescence (ECL) system.
Luciferase assays
The Fluc versus the Rluc activities of the (-1) and (0)
constructs were measured as relative light units with a
Berthold Lumat LB 9507 luminometer, as previously
described (8). A Dual-Luciferase Reporter Assay System
kit (Promega) was used for Jurkat cells and home-made
reagents (25) were used for 293T cells. The Rluc activity is
used to normalize the Fluc activity (Fluc/Rluc). The
frameshift eﬃciency is equal to:
½Flucð 1Þ=Rlucð 1Þ =
½Flucð0Þ=Rlucð0ÞþFlucð 1Þ=Rlucð 1Þ :
RESULTS
Inhibition ofcap-dependent translation initiation with
specific inhibitors increases HIV-1 frameshift efficiency
Our aim was to investigate whether the presence of TAR
aﬀects HIV-1 frameshift eﬃciency in relationship with its
eﬀect on cap-dependent translation initiation. To this end,
we used a dual-luciferase construct, pDual-HIV(–1),
which contains the Rluc and the Fluc reporter genes
separated by the HIV-1 frameshift region (Figure 1B). In
this construct, the Fluc is produced only by ribosomes that
make a –1 frameshift when translating the HIV-1 frame-
shift region. To assess the frameshift eﬃciency, we used a
control construct, pDual-HIV(0), in which an adenine is
added after the slippery sequence in the frameshift region,
so that the Fluc coding sequence is in-frame with the Rluc
coding sequence. The Rluc is synthesized by conventional
translation in both (-1) and (0) constructs. Before
investigating the eﬀect of TAR, we veriﬁed that changes
in cap-dependent translation initiation aﬀect HIV-1
frameshift eﬃciency. Jurkat cells, a CD4+ T-cell line,
were transfected with pDual-HIV(-1) or (0) plasmids and
treated with thapsigargin, rapamycin or hippuristanol,
three inhibitors perturbing a diﬀerent step of cap-
dependent translation initiation (Figure 1A). The frame-
shift eﬃciency, which is 5.1 0.4% in the absence of
inhibitors, was increased about twofold in the presence
of either one of these three inhibitors (Figure 1C).
The presence of ahighamount ofTAR decreases HIV-1
frameshift efficiency
We next assessed the eﬀect of TAR on the frameshift
eﬃciency. TAR (Figure 2A) was inserted at about 40nt
from the 50 end of the mRNA in pDual-HIV, generating
pDual-HIV-TAR(-1) and (0) (Figure 2B). We avoided
placing TAR at the very end of the mRNA, since such a
position could interfere with the binding of the 40S
subunit to the messenger (23,26,27 and references therein).
We ﬁrst examined the eﬀect of a high amount of TAR that
inhibits PKR and stimulates translation initiation (21).
The frameshift eﬃciency was assessed in Jurkat and 293T
cells. When 2mg of pDual-HIV-TAR were delivered into
the cells, the frameshift eﬃciency was decreased to 70% of
its value in absence of TAR in either Jurkat or 293T cells
(Figure 2C and D). Under the conditions of these assays,
the frameshift eﬃciency in absence of TAR was
6.1 0.2% in Jurkat cells and 11.3 0.9% in 293T cells.
These values, and the value of 5.1 0.4% observed in the
experiment described in the preceding section with Jurkat
cells that were transfected under slightly diﬀerent condi-
tions (see details in ‘Materials and Methods’ section), are
comparable to the values obtained with diﬀerent hetero-
logous systems containing the HIV-1 frameshift region,
which were shown to range between 2 and 10% in
mammalian cultured cells (8,22,28,29). It can be recalled
here that several groups observed that the absolute value
of the frameshift eﬃciencies changes, depending upon
various parameters such as the conditions used for the
assay and the type of cultured cells (30).
We then investigated whether the decrease in frameshift
eﬃciency observed with pDual-HIV-TAR was inﬂuenced
by the position of TAR in cis or in trans from the reporter
mRNA. Two other constructs were used, pDual-HIV-
50TAR, where the distance between TAR and the 50 end
of the reporter mRNA was increased by 50nt compared to
pDual-HIV-TAR, and pTAR, that provides TAR in trans
from the reporter mRNA expressed from pDual-HIV
(Figure 2B). The frameshift eﬃciency was decreased to 75
and 60%, respectively, in Jurkat cells and 293T cells
transfected with pDual-HIV-50TAR compared to the
value in absence of TAR. When Jurkat and 293T cells
were co-transfected with 2mg of pDual-HIV and 2mg
of pTAR, the frameshift eﬃciency was reduced to 70% of
its value in absence of TAR, a decrease similar to that
observed when TAR was present in cis of the reporter
mRNA (Figure 2C and D). These results indicate that
it is the presence of TAR in the cells and not its
presence in the reporter mRNA that decreases HIV-1
frameshift eﬃciency. The eﬀect of TAR on the frameshift
eﬃciency was conﬁrmed when using an infection system to
deliver the reporters into the cells (see Figure 1 in the
Supplementary Data).
Inhibiting PKR decreases HIV-1 frameshift efficiency
To verify that PKR was involved in the changes in HIV-1
frameshift eﬃciency observed with a high amount of
TAR, we created two constructs, pTARibulge
 
and pTARuucg
 , expressing mutants of TAR that
cannot bind PKR (31) (Figure 3A). When Jurkat cells
were co-transfected with pDual-HIV and plasmids gen-
erating these TAR mutants, the frameshift eﬃciencies
were similar to that obtained in absence of TAR and
signiﬁcantly higher than the value obtained in the presence
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PKR is involved in the changes of frameshift eﬃciency
observed in the presence of TAR.
To further conﬁrm that inhibiting PKR decreases
HIV-1 frameshift eﬃciency, a plasmid expressing Tat, a
HIV-1 viral protein, was co-transfected with the dual-
luciferase plasmids. In addition to its well-characterized
transactivation eﬀect on transcription of the viral mRNAs
by binding to TAR, Tat inﬂuences translation by
inhibiting PKR, either directly by binding this kinase or
indirectly by blocking the binding of TAR to PKR
(32,33). We used a Tat mutant (Tat
 ) that can bind TAR
and inhibit PKR but cannot transactivate transcription,
and, thereby, that does not aﬀect mRNA levels (24).
Jurkat cells were co-transfected with the plasmid coding
for this Tat mutant and with pDual-HIV, pDual-
HIV-TAR or pDual-HIV-50TAR. In the presence of
Tat
 , the frameshift eﬃciency was decreased to approxi-
mately 60% of its value in absence of Tat
  (Figure 3C).
The decrease with Tat
  was the same, whether TAR was
present or not, which suggests that Tat
  and TAR both act
via the same mechanism, the inhibition of PKR.
TAR increases or decreases HIV-1 frameshift efficiency
depending uponits concentration and this dose-dependent
effect ismediated by PKR
Next, we investigated the eﬀect of a small amount of
TAR, which activates PKR and thus interferes with
translation initiation (21). We used stable 293T transfec-
tants expressing a dual-luciferase HIV reporter. Stable
transfectants expressing a (-1) or (0) dual-luciferase HIV
reporter were transfected with pTAR, pTARibulge
  or
pTARuucg
  in amounts ranging from 0 to 2.3mg.
Figure 4A shows the eﬀect of wild-type TAR. In the
presence of a small quantity of TAR, the frameshift
eﬃciency increases to about 140% of its value in absence
of TAR but with a larger quantity of TAR, the frameshift
eﬃciency decreases to about 80%, a decrease comparable
to that observed with a transient transfection of pDual-
HIV (Figure 2). As a control, we used stable 293T
transfectants expressing Rluc and Fluc in-frame, separated
by a linker instead of the HIV-1 frameshift region. The
ratio of Fluc activity to Rluc activity in lysates from these
transfectants was unchanged in the presence of pTAR
(data not shown), conﬁrming that changes in the Fluc to
Rluc ratio observed with stable transfectants expressing
the dual-luciferase HIV reporter are due to variations in
the frameshift eﬃciency. When the stable 293T transfec-
tants expressing the dual-luciferase HIV reporter were
transfected with plasmids producing TAR mutants that
cannot bind PKR, the frameshift eﬃciency was unaltered
(Figure 4B). The eﬀect of a low amount of TAR was also
assessed by transient co-transfection of Jurkat cells with
pDual-HIV and diﬀerent quantities of pTAR, ranging
from 0 to 2mg, the ratio of pTAR to pDual-HIV being
equal or inferior to 1:1. The frameshift eﬃciency also
Figure 2. HIV-1 frameshift eﬃciency decreases when a high amount of
TAR is present. (A) Sequence and structure of wild-type TAR RNA.
(B) Plasmids pDual-HIV-TAR and pDual-HIV-50TAR are derivatives
of pDual-HIV with the TAR-coding sequence inserted, respectively,
about 40nt downstream from the CMV promoter or at an additional
distance of 50nt from this promoter. Plasmid pTAR generates the free
TAR sequence in trans from the reporter mRNA expressed from
pDual-HIV. The frameshift eﬃciency was assessed in lysates from
Jurkat cells (C) and 293T cells (D) transfected with 2mg of pDual-HIV
or pDual-HIV-TAR or pDual-HIV-50TAR or co-transfected with 2 mg
of pDual-HIV and 2mg of pTAR. The frameshift eﬃciency with Jurkat
cells and 293T cells transfected with pDual-HIV was arbitrarily set
at 100% in (C) and (D), respectively. Results are the means SD of at
least four independent experiments. The P-values, calculated according
to the Student’s t-test, are indicated.
34 Nucleic Acids Research, 2008, Vol. 36,No. 1increases under the conditions corresponding to low
amounts of TAR, the highest increase being  140% of
the frameshift eﬃciency without TAR (data not shown).
We investigated the involvement of PKR in the changes
in frameshift eﬃciency observed with a low amount of
TAR. To this end, PKR expression was silenced by
transfecting a PKR siRNA mix into stable 293T
transfectants expressing a dual-luciferase HIV reporter.
After 24h, cells were transfected with pTAR in diﬀerent
amounts and harvested 48h later. As a negative control,
an eGFP siRNA mix targeting GFP was used. In the
presence of the eGFP siRNA, the frameshift eﬃciency
increases when TAR is present. However, when PKR
expression is silenced, this eﬀect disappears, supporting
that it is related to PKR activation (Figure 5A). Eﬀective
silencing of PKR is achieved under the conditions of
the assay as shown in Figure 5B. It can be noted that
the response of the cells to the increase in the amount
of TAR appears to diﬀer from that in Figure 4. This is
due to a diﬀerence in the experimental protocol result-
ing in a lower ratio of the quantity of transfected pTAR
to the number of cells (see ‘Materials and Methods’
section).
DISCUSSION
Using a dual-luciferase reporter system in Jurkat and
293T cells, we showed that the presence of TAR alters
Figure 3. PKR is involved in the decrease in HIV-1 frameshift eﬃciency observed when a high amount of TAR is present. (A) Sequence and
structure of TAR mutants that cannot bind PKR (31) used in this study. (B) The frameshift eﬃciency is not aﬀected by the TAR mutants. The
frameshift eﬃciency was assessed in lysates from Jurkat cells co-transfected with pDual-HIV and plasmids expressing wild-type TAR or mutants of
TAR. The frameshift eﬃciency with pDual-HIV was arbitrarily set at 100%. Results are the means SD of at least ﬁve independent experiments.
The P values are indicated. The values with pDual-HIV and pTARbulge
  or pDual-HIV and pTARuucg
  were not signiﬁcantly diﬀerent from the
value with pDual-HIV, but were signiﬁcantly higher than the value with pDual-HIV and pTAR. (C) The presence of a Tat mutant (Tat
 ) that
inhibits PKR decreases the frameshift eﬃciency. The frameshift eﬃciency was assessed in lysates from Jurkat cells co-transfected with pDual-HIV,
pDual-HIV-TAR or pDual-HIV-50TAR and a plasmid coding for Tat
  or an empty vector in a 1:1 ratio. The frameshift eﬃciency with pDual-HIV
without Tat
  was arbitrarily set at 100%. Results are the means SD of at least four independent experiments. The P-values are indicated. The
values with pDual-HIV-TAR and pDual-HIV-50TAR, with or without Tat
 , were not signiﬁcantly diﬀerent from the value with pDual-HIV with
Tat
  but signiﬁcantly lower than the value with pDual-HIV without Tat
 .
Figure 4. Wild-type TAR, but not the TAR mutants, increases or decreases HIV-1 frameshift eﬃciency in a dose-dependent manner. The frameshift
eﬃciency was assessed in lysates from stable 293T transfectants expressing the (-1) or (0) dual-luciferase HIV reporter transfected with pTAR (A),
pTARibulge
  (B) or pTARuucg
  (B) in diﬀerent amounts ranging from 0 to 2.3mg. The asterisks indicate the frameshift eﬃciencies that
signiﬁcantly diﬀer from the frameshift eﬃciency without pTAR (P<0.0005). Results are the means SD of at least six independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 1 35HIV-1 frameshift eﬃciency. The addition of a high
amount of TAR, in cis or in trans of the reporter
mRNA, decreases the frameshift eﬃciency. This eﬀect is
related to an inhibition of PKR. Conversely, a low
amount of TAR increases the frameshift eﬃciency, by
activating PKR.
Activation or inhibition of PKR is well-known to
aﬀect translation initiation via changes in eIF2 phosphor-
ylation (reviewed in 21). However, it is also known
that transformed cells, such as those we used in this
study, tolerate a certain degree of endoplasmic reticulum
stress leading to a certain level of phosphorylation of eIF2
via PERK, a kinase functionally homologous to PKR
(34). Our experimental conditions do not drastically
aﬀect the expression of our reporters, implying that the
changes in the translation initiation rate caused by
activation or inhibition of PKR are small and that
the changes in eIF2 phosphorylation should be modest.
Using western blotting, we could not detect signiﬁcant
variations in the phosphorylation level of eIF2 in 293T
or Jurkat cells transfected with diﬀerent quantities of
TAR (data not shown). We nevertheless suggest that the
eﬀect of PKR on HIV-1 frameshift eﬃciency results
from changes in eIF2 phosphorylation that are too
small to be detected in presence of the endogenous
signal for phosphorylated eIF2 in these cells. However,
we cannot exclude that PKR could also inﬂuence HIV-1
frameshift eﬃciency via another yet undiscovered
mechanism.
Contradictory eﬀects were seen in previous observations
on the inﬂuence of the translation initiation rate on
the frameshift eﬃciency. The frameshift eﬃciency of a
plant virus, the beet western yellow virus (BWYV), was
higher in a reticulocyte lysate than in a wheat germ
extract, which has a lower rate of translation initiation
(35). Also, the frameshift eﬃciency of the human T-cell
leukemia virus type II (HTLV-2), when measured in
a reticulocyte lysate, was higher with capped than with
uncapped mRNAs, which have a lower rate of translation
initiation (36). These observations disagree with our
results that show a negative relationship between the
rate of translation initiation and the frameshift eﬃciency.
However, Paul et al. (37), when comparing the frameshift
eﬃciency of the barley yellow dwarf virus (BYDV)
with capped and uncapped mRNAs in a yeast extract,
found that increasing the translation initiation rate
decreased the frameshift eﬃciency. Furthermore,
Lopinski et al. (38), who investigated in vivo the eﬀect of
a reduced translation initiation rate on the frameshift
eﬃciency of the L-A virus of S. cerevisiae, found that this
eﬃciency was increased under these conditions. The
results of Paul et al. (37) and Lopinski et al.(38) are in
perfect agreement with our ﬁndings, and, in line with
them, we present the following model that explains our
results (Figure 6).
When a ribosome translates the HIV-1 frameshift
region, it encounters the frameshift stimulatory signal
and makes a pause, its decoding center covering the
slippery sequence (39–41). During the pause, the ribosome
can shift or not the reading frame, and, after the pause, the
ribosome unfolds the frameshift stimulatory signal and
translation continues. If the upstream ribosome reaches
the frameshift region before the signal has refolded, the
probability that the frameshift occurs is extremely weak.
The spacing between ribosomes translating the HIV-1
frameshift region, which is determined by the rate of
translation initiation [basal rate estimated to about one
initiation event every 6.5s (42)], could thus aﬀect the
frameshift eﬃciency. Therefore, if we assume an average
elongation speed of ﬁve amino acids per second per
ribosome, corresponding to a displacement of 15nt per
second on the mRNA (42), the minimal distance between
the decoding centers of two ribosomes translating a
mRNA would be of about 100nt. A ribosome covers
about 32nt on the mRNA and heel-printing studies
showed that the ﬁrst base of the P-site codon is at a
distance of 12nt from the 50 edge of the ribosome and of
20nt from the 30 edge (43). From these calculations, there
would be about 70 exposed nt between two elongating
ribosomes. Thus, the HIV-1 frameshift region, including
the 43-nt frameshift stimulatory signal, would be exposed
after the passage of the ﬁrst ribosome. The signal would
then re-form, which takes only a few microseconds (44),
Figure 5. The eﬀect of TAR on HIV-1 frameshift eﬃciency disappears
when PKR expression is silenced. (A) The frameshift eﬃciency was
assessed in lysates from stable 293T transfectants expressing the (-1) or
(0) dual-luciferase HIV reporter and transfected ﬁrst with a eGFP
siRNA mix (negative control) or a PKR siRNA mix, and, after 24h,
with pTAR in diﬀerent amounts ranging from 0 to 2.3mg. Results are
the means SD of at least three independent experiments. (B) Control
of the silencing of PKR expression. Equal amounts of proteins from
lysates of stable 293T transfectants expressing a dual-luciferase HIV
reporter and transfected with either the eGFP siRNA mix (lane 1) or
PKR siRNA mix (lane 2) were separated by SDS–PAGE, transferred
on a nitrocellulose membrane and immunoblotted with a mouse anti-
PKR monoclonal antibody. Anti-a-tubulin blotting was used as an
internal control for loading.
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mRNA containing the sequence of this signal. However,
the pause made by the ﬁrst ribosome when encountering
the signal decreases the distance with the following
ribosome, which has continued to progress during the
pause of the ﬁrst ribosome. This second ribosome could
reach the region corresponding to the stimulatory signal
before this signal could refold, being still partially covered
by the ﬁrst ribosome. A pause of about three seconds for
the ﬁrst ribosome is suﬃcient to prevent the refolding of
the stimulatory signal. The second ribosome would thus
avoid frameshifting and the spacing between this ribosome
and the third ribosome would not be altered. As a
consequence, the third ribosome would encounter the
stimulatory signal and pause, and frameshifting would be
possible. This analysis shows that the signal aﬀects every
other ribosome under basal conditions. According to this
model, an increase in the rate of translation initiation
would decrease the frameshift eﬃciency, since ribosomes
would be closer to each other and a smaller proportion of
ribosomes would encounter the folded frameshift stimu-
latory signal. Conversely, a decrease in translation
initiation would increase the frameshift eﬃciency since
ribosomes would be further apart and it is very likely that
each ribosome would encounter the folded signal.
Interestingly, Lopinski et al. (38), when studying the
eﬀect of a reduced translation initiation rate with the
L-A virus in yeast cells, observed that the frameshift
eﬃciency doubled, independently of the severity of the
initiation defect. Their interpretation was that every other
ribosome encounters the signal under basal conditions and
that, with a reduced initiation rate, every ribosome
encounters this signal. Our analysis fully supports this
interpretation.
Figure 6. Changes in the rate of translation initiation inﬂuence the frameshift eﬃciency by modifying the spacing between elongating ribosomes. This
model shows elongating ribosomes that reach the frameshift region and explains how the rate of translation initiation, which determines the spacing
between these ribosomes, aﬀects the frameshift eﬃciency (see the text). Note that a ribosome must encounter a folded frameshift stimulatory signal to
make a frameshift, but this encounter does not ensure that frameshifting will occur.
Nucleic Acids Research, 2008, Vol. 36, No. 1 37Although HIV-1 does not induce a rapid and dramatic
global shutdown of host cell translation following
infection, in contrast to other viruses such as poliovirus,
cap-dependent translation initiation is decreased due to
cellular stress following infection by this virus (25,45)
and this decrease can be related to PKR activation (46).
Our results suggest that a change in cap-dependent
translation initiation could aﬀect HIV-1 frameshift
eﬃciency in infected cells. As mentioned in the
‘Introduction’ section, the virus replication appears to
be exquisitely sensitive to changes in frameshift eﬃciency.
Given the detrimental eﬀect of such changes, the virus
likely uses various strategies to counteract this eﬀect.
One strategy is inhibition of PKR (reviewed in 25,47)
to stimulate translation initiation. HIV-1 uses two
major ways to inhibit PKR: its Tat protein inhibits
PKR and its TAR RNA structure blocks PKR dimeriza-
tion when present in large quantities. TAR is located
at the 50 and 30 end of all HIV-1 mRNAs and is also
present under a free cytoplasmic form of 58-66nt (17,18).
All these forms of TAR can participate in the inhibition
of PKR.
However, inhibition of cap-dependent translation
initiation can occur independent of PKR activation.
Indeed, the HIV-1 Vpr protein is capable of inducing
G2 arrest in cultured CD4+ T cells (48,49 and references
therein), and, during such arrest, cap-dependent transla-
tion initiation is severely impaired (50). Another possible
strategy to circumvent the problem caused by this
situation is the use of a cap-independent mechanism by
HIV-1 to initiate the translation of its full-length mRNA
(25,45). The virus would thus continue to express Gag and
Gag-Pol and would maintain a frameshift eﬃciency that is
optimal for its replication. An internal ribosomal entry
site (IRES) was identiﬁed in the 50UTR region of HIV-1
full-length mRNA (51) and another IRES was found in
the beginning of the gag coding sequence (52). IRES have
also been found in HIV type 2 (53) and in simian
immunodeﬁciency virus (54), two viruses related to HIV-1.
However, the use of an IRES by HIV-1 in the context of
replication-competent viruses remains to be proven (45).
The two strategies that are described above are not
mutually exclusive. HIV-1 could ﬁrst counteract changes
in cap-dependent translation initiation by inhibiting PKR,
until a larger stress in the cellular environment severely
perturbs cap-dependent initiation. The virus would then
switch to an IRES-driven mode to translate its full-length
mRNA.
This scheme is deduced from studies in cultured cells
and it will now be important to investigate the frameshift
eﬃciency in the context of a viral infection. A detailed
understanding of the mechanisms used by HIV-1 to
control its frameshift eﬃciency will provide valuable
information for the design of drugs targeting the frame-
shift event.
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